These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8977279)

  • 1. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
    Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disease-related epitope of Torpedo acetylcholine receptor. Residues involved in I-Ab binding, self-nonself discrimination, and TCR antagonism.
    Wall KA; Hu JY; Currier P; Southwood S; Sette A; Infante AJ
    J Immunol; 1994 May; 152(9):4526-36. PubMed ID: 8157967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes.
    Infante AJ; Thompson PA; Krolick KA; Wall KA
    J Immunol; 1991 May; 146(9):2977-82. PubMed ID: 1707927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide.
    Wauben MH; Joosten I; Schlief A; van der Zee R; Boog CJ; van Eden W
    J Immunol; 1994 Apr; 152(8):4211-20. PubMed ID: 7511673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptides.
    Wauben MH; Kozhich A; Joosten I; Schlief A; Boog CJ; van Eden W
    Eur J Immunol; 1994 May; 24(5):1053-60. PubMed ID: 7514128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
    Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
    Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
    J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
    Zoda T; Yeh TM; Krolick KA
    J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY; Qiao J; Melms A; Link H
    Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
    Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
    J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self and non-self peptides treat autoimmune encephalomyelitis: T cell anergy or competition for major histocompatibility complex class II binding?
    Gautam AM
    Eur J Immunol; 1995 Jul; 25(7):2059-63. PubMed ID: 7542603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amino acid substitutions within the region 62-76 of I-A beta b on binding with and antigen presentation of Torpedo acetylcholine receptor alpha-chain peptide 146-162.
    Oshima M; Atassi MZ
    J Immunol; 1995 May; 154(10):5245-54. PubMed ID: 7537303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism of cellular immunity accommodation in prophylactic effects of nasal tolerance with dual analogue on experimental autoimmune myasthenia gravis in Lewis rats].
    Wang LH; Wang HB; Tian QH; Fu YH; Wang WZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2004 Jul; 38(4):244-7. PubMed ID: 15312583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.